Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This is a study of the tolerability and safety of neoadjuvant dapagliflozin for patients with
high-risk or very high risk prostatic adenocarcinoma prior to radical prostatectomy. The
primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is
well-tolerated and safe to use in this patient population.